Highlight Therapeutics

Highlight Therapeutics is a clinical-stage biotech pioneering intra-lesional RNA therapies to activate the immune system against cancer, with a primary focus on skin cancers. The company's lead asset, BO-112, is in Phase 2b development for basal cell carcinoma (BCC) and has shown promise in combination with anti-PD-1 agents. Leveraging a unique approach to convert immunologically 'cold' tumors 'hot,' Highlight aims to address significant unmet needs in dermato-oncology, a field with a large and growing patient population. The company operates as a private, pre-revenue entity advancing its pipeline through clinical trials.

Intra-lesional delivery of synthetic double-stranded RNA (dsRNA) mimics designed to activate multiple innate immune pathways (e.g., TLR3, MDA5, PKR) to convert immunologically 'cold' tumors into 'hot,' T-cell-inflamed tumors.

Highlight competes in the dermato-oncology space with other intralesional/topical therapies (e.g., ingenol mebutate, imiquimod), advanced surgical methods, and systemic immunotherapies (e.g., cemiplimab for CSCC). Its differentiation lies in its unique RNA-based mechanism designed to convert 'cold' tumors and its potential for combination synergy with checkpoint inhibitors.